Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study.

TaŞdemİr, Mehmet; Canpolat, NUR; Yildiz, Nurdan; ÖzÇelİk, GÜl; Benzer, Meryem; Saygili, SEHA; Özkayin, Emİne; TÜrkkan, Özde; Balat, AyŞe; Candan, Cengİz; Çelakil, Mehtap; Yavuz, Sevgİ; Akinci, Nurver; GÖknar, NİlÜfer; AkgÜn, Cİhangİr; TÜlpar, Sebahat; Alpay, Harİka; Sever, Fatma; Bİlge, İlmay

doi:10.3906/sag-2012-297

Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study.

TaŞdemİr M., Canpolat N., Yildiz N., ÖzÇelİk G., Benzer M., Saygili S. K., ...Daha Fazla

Turkish journal of medical sciences, cilt.51, ss.1781-1790, 2021 (SCI-Expanded, Scopus, TRDizin)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 51
Basım Tarihi: 2021
Doi Numarası: 10.3906/sag-2012-297
Dergi Adı: Turkish journal of medical sciences
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.1781-1790
Anahtar Kelimeler: Frequently relapsing nephrotic syndrome, immunosuppressive agents, steroid-dependent nephrotic syndrome, steroid-resistant nephrotic syndrome, remission, CHILDHOOD-ONSET, FOLLOW-UP, CYCLOSPORINE
İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen.